CN1110553C - 基因工程腺病毒及其用途 - Google Patents
基因工程腺病毒及其用途 Download PDFInfo
- Publication number
- CN1110553C CN1110553C CN98103219A CN98103219A CN1110553C CN 1110553 C CN1110553 C CN 1110553C CN 98103219 A CN98103219 A CN 98103219A CN 98103219 A CN98103219 A CN 98103219A CN 1110553 C CN1110553 C CN 1110553C
- Authority
- CN
- China
- Prior art keywords
- cell
- adenovirus
- virus
- defective
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 title description 34
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 25
- 241000700605 Viruses Species 0.000 claims description 44
- 230000002950 deficient Effects 0.000 claims description 25
- 230000003612 virological effect Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 85
- 238000012360 testing method Methods 0.000 abstract description 7
- 238000010353 genetic engineering Methods 0.000 abstract 4
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 21
- 230000008859 change Effects 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 6
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102000052575 Proto-Oncogene Human genes 0.000 description 5
- 108700020978 Proto-Oncogene Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000008187 granular material Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 108700025694 p53 Genes Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102220002645 rs104894309 Human genes 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000007849 functional defect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101710199711 Early E1A protein Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101150020201 RB gene Proteins 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 101710136524 X polypeptide Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
天数 | 第1组 | 第2组 | 第3组 | 第4组 | 对照组 |
0天 | 100 | 100 | 100 | 100 | 100 |
7 | 85.87 | 142.55 | 160.35 | 242.85 | 245.19 |
14 | 84.78 | 139.08 | 189.80 | 235.94 | 354.16 |
21 | 75.02 | 161.66 | 244.28 | 274.31 | 424.55 |
28 | 63.51 | 216.88 | 276.37 | 300.03 | 545.92 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98103219A CN1110553C (zh) | 1998-07-15 | 1998-07-15 | 基因工程腺病毒及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98103219A CN1110553C (zh) | 1998-07-15 | 1998-07-15 | 基因工程腺病毒及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1241632A CN1241632A (zh) | 2000-01-19 |
CN1110553C true CN1110553C (zh) | 2003-06-04 |
Family
ID=5217805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98103219A Expired - Lifetime CN1110553C (zh) | 1998-07-15 | 1998-07-15 | 基因工程腺病毒及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1110553C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108338994A (zh) * | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
US10980859B2 (en) | 2013-09-02 | 2021-04-20 | Hangzhou Converd Co., Ltd. | In vivo individualized systemic immunotherapeutic method and device |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1506021B1 (de) * | 2002-05-27 | 2019-05-01 | Per Sonne Holm | Verwendung von adenoviren und dafur kodierenden nukleinsäuren |
CN1528887A (zh) * | 2003-10-15 | 2004-09-15 | 中国科学院上海生命科学研究院 | 肿瘤靶向双基因-病毒的构建方法 |
ES2358204T3 (es) | 2004-05-26 | 2011-05-06 | Bayer Schering Pharma Aktiengesellschaft | Adenovirus quiméricos para uso en el tratamiento del cáncer. |
EP2675483B1 (en) * | 2011-02-18 | 2018-09-19 | The UAB Research Foundation | Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase prodrug related applications |
AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
KR20240032177A (ko) | 2015-04-30 | 2024-03-08 | 싸이오서스 테라퓨틱스 엘티디. | B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스 |
EA201891021A1 (ru) | 2015-12-17 | 2018-11-30 | Псайоксус Терапьютикс Лимитед | Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
SG11201901716TA (en) | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
-
1998
- 1998-07-15 CN CN98103219A patent/CN1110553C/zh not_active Expired - Lifetime
Non-Patent Citations (3)
Title |
---|
SCIENCE274(5268) 1996-10-18 Bischoff JR An adenovirus mutant that repIicates seIectiveIY inp53-deficient human tumor ceIIs * |
SCIENCE274(5268) 1996-10-18 Bischoff JR An adenovirus mutant that repIicates seIectiveIY inp53-deficient human tumor ceIIs;中国地方病学杂志17(2) 1998-03-01 介导野生型P53基因转移的重组腺病毒的构建研究基因工程腺病毒及其用途 * |
中国地方病学杂志17(2) 1998-03-01 介导野生型P53基因转移的重组腺病毒的构建研究基因工程腺病毒及其用途 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10980859B2 (en) | 2013-09-02 | 2021-04-20 | Hangzhou Converd Co., Ltd. | In vivo individualized systemic immunotherapeutic method and device |
CN108338994A (zh) * | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
US11357804B2 (en) | 2017-01-25 | 2022-06-14 | Hangzhou Converd Co., Ltd. | Application of oncolytic viruses as immunostimulants for treatment of tumors and/or cancers |
Also Published As
Publication number | Publication date |
---|---|
CN1241632A (zh) | 2000-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wollmann et al. | Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates | |
TWI704226B (zh) | 重組溶瘤病毒組合物及其用途 | |
Taguchi et al. | Current status of clinical trials assessing oncolytic virus therapy for urological cancers | |
CN1110553C (zh) | 基因工程腺病毒及其用途 | |
CN103614416A (zh) | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 | |
Endo et al. | In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer | |
CN1455674B (zh) | 绵羊副痘病毒菌株用于制备抗病毒药物和抗癌药物的用途 | |
CN110996980A (zh) | 一种用于治疗肿瘤的病毒 | |
CN1333689A (zh) | 用腺病毒突变体杀伤肿瘤和肿瘤相关内皮细胞的方法 | |
CN105031630A (zh) | 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法 | |
Ganly et al. | Current role of gene therapy in head and neck cancer | |
WO2024199391A1 (zh) | 重组鼠伤寒沙门氏菌基因工程菌hcs1、菌剂及其应用 | |
CN1528887A (zh) | 肿瘤靶向双基因-病毒的构建方法 | |
CN113699122B (zh) | 一种多基因融合溶瘤腺病毒及其构建方法和应用 | |
CN1294268C (zh) | 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体 | |
CN1177057C (zh) | 病毒载体与人肿瘤抑制基因的重组体及其应用 | |
JPWO2005103237A1 (ja) | 組換え単純ヘルペスウイルスの作製方法 | |
CN116144607A (zh) | 一种溶瘤病毒及其应用 | |
CN101643750B (zh) | 靶向性溶肿瘤腺病毒载体Ad-TD-gene的构建方法及应用 | |
CN1793343A (zh) | 具有肿瘤靶向性和肿瘤自杀性的溶瘤性抗癌重组腺病毒 | |
CN1213004A (zh) | 重组白细胞介素-2腺病毒载体及产生方法 | |
WO2020034051A1 (en) | Methods and compositions for treatment of solid cancers and microbial infection | |
US7655459B2 (en) | Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer | |
CN1094974C (zh) | 表达人白细胞介素12的重组腺病毒及其制法和用途 | |
CN1699581A (zh) | 肿瘤靶向基因-病毒zd55-il-24及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI SANWEI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: HANGZHOU SAISHI BIOLOGICAL TECHNOLOGY DEVELOPMENT CO. LTD. Effective date: 20040407 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20040407 Address after: 201206, No. 1150, GUI Qiao Road, Shanghai, Pudong New Area Patentee after: Shanghai Sanwei Biotech Co., Ltd. Address before: 100081 Beijing City, Haidian District, No. 7 B Zhang Hui Patentee before: Hangzhou Saishi Biological Technology Development Co., Ltd. |
|
PP01 | Preservation of patent right |
Effective date of registration: 20101119 Granted publication date: 20030604 |
|
PD01 | Discharge of preservation of patent |
Date of cancellation: 20111119 Granted publication date: 20030604 |
|
ASS | Succession or assignment of patent right |
Owner name: YU DECHAO Effective date: 20120426 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Yu Dechao Inventor before: Zhang Hui |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG HUI TO: YU DECHAO |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120426 Address after: 201206, No. 1150, GUI Qiao Road, Shanghai, Pudong New Area Co-patentee after: Yu Dechao Patentee after: Shanghai Sanwei Biotech Co., Ltd. Address before: 201206, No. 1150, GUI Qiao Road, Shanghai, Pudong New Area Patentee before: Shanghai Sanwei Biotech Co., Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20030604 |